---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-089680"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T06:00:11.991999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1

## Summary
- CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.
- Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.
- Jensen will also be interviewed by Oxford Global's editorial team for their online portal.
- Jensen available for one-on-one meetings during the conference to discuss business development.
- Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib.

## SEC filing metadata
- accession: 0001213900-25-089680
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/0001213900-25-089680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/ea0258005-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-089680
- JSON: https://secwatch.observer/filing/0001213900-25-089680.json
- Plain text: https://secwatch.observer/filing/0001213900-25-089680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.